3. A novel polypeptide having an amino acid sequence of natural human Fas ligand wherein all of the 8th amino acid to 69th amino acid residues as measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted or substituted, and at least one amino acid residue of from N1th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted or substituted.

4. A novel polypeptide including the amino acid sequence described in SEQ ID NO. 1 or 2.

 $(1)^{5}$. A DNA coding for the novel polypeptide of claim 2.

 $\mathcal{L}_{\text{apoptosis.}}^{\nu}$ 6. A soluble Fas ligand which inhibits Fas-mediated

Please add the following new claims.

--8. A DNA coding for the novel polypeptide of claim 3.--

--9. A DNA coding for the novel polypeptide of claim 4.--

 $--10\,.$ A novel polypeptide having an amino acid sequence of natural human Fas ligand wherein the $129^{\rm th}$ amino acid and $130^{\rm th}$

0 p

Docket No. 1110-266P

amino acid residues as measured from N terminal end are both deleted or substituted, and at least one amino acid residue of from 111th amino acid to 128th amino acid residues or at least one amino acid residue of from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted or substituted, wherein said novel polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.--

 M_{2}^{M}

Const

--11. A novel polypeptide having an amino acid sequence of natural human Fas ligand wherein all of the 8th amino acid to 69th amino acid residues as measured from N terminal end are deleted, 129th amino acid and 130th amino acid residues as measured from N terminal end are both deleted or substituted, and at least one amino acid residue of from 111th amino acid to 128th amino acid residues or at least one amino acid residues from 131st amino acid to 133rd amino acid residues as measured from N terminal end is deleted or substituted wherein said novel polypeptide has membrane binding activity and induces Fas-mediated apoptotic activity.--